Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MangoceuticalsMGRX -2.06%26 EV-to-EBITDA is -0.68 as of Aug. 18, 2026. GuruFocus rates MGRX with a GF Score™ of 26/100 and a GF Value™ of $0.19 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 510 Healthcare Providers & Services companies, Mangoceuticals ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Mangoceuticals's enterprise value is $9.17 Mil.
Mangoceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was $-13.39 Mil. Therefore, Mangoceuticals's EV-to-EBITDA for today is -0.68.
The historical rank and industry rank for Mangoceuticals's EV-to-EBITDA or its related term are showing as below:
MGRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.76 Med: -0.84 Max: -0.06
Current: -0.68
During the past 5 years, the highest EV-to-EBITDA of Mangoceuticals was -0.06. The lowest was -18.76. And the median was -0.84.
MGRX's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Healthcare Providers & Services industry
Industry Median: 10.685
vs MGRX: -0.68
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Mangoceuticals's PE Ratio (TTM) for today is calculated as:
Mangoceuticals's share price for today is $0.5255.
Mangoceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Mangoceuticals's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Mangoceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mangoceuticals EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Mangoceuticals's EV-to-EBITDA falls into.
Mangoceuticals's current Enterprise Value is $9.17 Mil.
Mangoceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mangoceuticals (MGRX) has a EV-to-EBITDA of -0.68 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mangoceuticals. According to the industry distribution chart, Mangoceuticals ranks #999999 out of 510 companies in the Healthcare Providers & Services industry.
Is Mangoceuticals' EV-to-EBITDA too high?
Mangoceuticals' current EV-to-EBITDA is -0.68. Based on the distribution chart, Mangoceuticals ranks #999999 out of 510 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Mangoceuticals has a GF Score™ of 26/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Mangoceuticals' EV-to-EBITDA compare to PBSV and VYND?
According to the Healthcare Providers & Services industry distribution chart, Mangoceuticals ranks #999999 out of 510 companies for EV-to-EBITDA. This places Mangoceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 10.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.69, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Mangoceuticals. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mangoceuticals's current EV-to-EBITDA is -0.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mangoceuticals stock overvalued right now?
Based on GuruFocus' analysis, Mangoceuticals (MGRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.19, compared to a current price of $0.53 — trading 176.6% above its estimated fair value. The current EV-to-EBITDA is -0.68. Mangoceuticals' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Mangoceuticals (MGRX), the current EV-to-EBITDA is -0.68 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mangoceuticals (MGRX) Overvalued in 2026?
Based on GuruFocus' analysis, Mangoceuticals stock appears to be overvalued.
The current stock price of $0.53 is trading 176.6% above its estimated GF Value™ of $0.19.
GuruFocus considers Mangoceuticals to be Significantly Overvalued.
Key valuation signals for MGRX:
EV-to-EBITDA: -0.68
GF Value™: $0.19 vs. price of $0.53 (176.6% above fair value)
No single metric tells the full story. See the MGRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.
26GF Score
Get the complete analysis for MGRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGRX has been successfully added to your 
